2012
Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression?
Dawes SE, Palmer BW, Meeks T, Golshan S, Kasckow J, Mohamed S, Zisook S. Does Antidepressant Treatment Improve Cognition in Older People with Schizophrenia or Schizoaffective Disorder and Comorbid Subsyndromal Depression? Neuropsychobiology 2012, 65: 168-172. PMID: 22456094, PMCID: PMC3701889, DOI: 10.1159/000331141.Peer-Reviewed Original ResearchConceptsSchizoaffective disorderCognitive deficitsDepression Rating Scale scoresHamilton Depression Rating ScaleFlexible-dose treatmentAntidepressant treatment responseDepression Rating ScaleTreatment of depressionMajor depressive disorderRating Scale scoresBaseline cognitive statusPlacebo groupAntidepressant medicationCurrent medicationsPlacebo augmentationFunctional disabilityCognitive composite scoreSubsyndromal depressionDepressive disorderSubsyndromal symptomsTreatment responseTreatment groupsDose treatmentScale scoreCognitive status
2008
Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia
Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. Schizophrenia Bulletin 2008, 35: 336-346. PMID: 18586692, PMCID: PMC2659303, DOI: 10.1093/schbul/sbn067.Peer-Reviewed Original ResearchConceptsPositive medication attitudesMedication attitudesSymptoms of schizophreniaSchizophrenia symptomsGreater medication complianceDrug Attitude InventoryRelationship of insightClinical Antipsychotic TrialsTreatment Attitudes QuestionnaireGreater patient understandingLevel of depressionMixed model regression analysisLower symptom levelsRecovery-oriented servicesClinical outcomesMedication adherenceMedication complianceChronic schizophreniaAntipsychotic TrialsPatient understandingModel regression analysisMedicationsCommunity functioningPsychosocial rehabilitationSymptomsRelationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia
Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. American Journal Of Psychiatry 2008, 165: 978-987. PMID: 18450928, DOI: 10.1176/appi.ajp.2008.07111713.Peer-Reviewed Original Research
2006
Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia
Mohamed S, Bondi MW, Kasckow JW, Golshan S, Jeste DV. Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia. International Journal Of Geriatric Psychiatry 2006, 21: 711-718. PMID: 16862606, DOI: 10.1002/gps.1528.Peer-Reviewed Original ResearchConceptsAlcohol abuse/dependenceAbuse/dependenceSchizophrenia patientsCognitive statusAlcohol useHigher cognitive functionsWorse cognitive scoresQuality of lifeYounger schizophrenia patientsOlder groupNeuropsychological functioningNeurocognitive functioningCognitive functionCognitive scoresWorse cognitionIntervention researchCognitionDiagnosis of schizophreniaSame-aged groupPsychopathologic assessmentSchizoaffective disorderSymptom profilesLater lifeAge groupsSchizophrenia
2005
Stability of Cognitive Performance in Older Patients With Schizophrenia: An 8-Week Test-Retest Study
Harvey PD, Palmer BW, Heaton RK, Mohamed S, Kennedy J, Brickman A. Stability of Cognitive Performance in Older Patients With Schizophrenia: An 8-Week Test-Retest Study. American Journal Of Psychiatry 2005, 162: 110-117. PMID: 15625208, DOI: 10.1176/appi.ajp.162.1.110.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAlgorithmsAmbulatory CareAntipsychotic AgentsCognition DisordersFemaleFollow-Up StudiesHumansMaleMiddle AgedNeuropsychological TestsPsychiatric Status Rating ScalesPsychometricsPsychomotor PerformanceReproducibility of ResultsSchizophreniaSchizophrenic PsychologySeverity of Illness IndexConceptsCognitive measuresCognitive performancePractice effectsComprehensive neuropsychological test batteryTest scoresReliable change index methodCognitive-enhancing medicationsNeuropsychological test batteryCognitive test scoresSignificant test-retest correlationsModest cognitive improvementTest-retest correlationsTest-retest performanceCognitive improvementTest batterySecond-generation antipsychotic medicationsTest-retest errorSchizophrenia patientsRetest studyAntipsychotic medicationAlternate formsConventional antipsychotic medicationsSchizophreniaSpurious improvementPrior studies
2004
Bipolar Disorder in Middle-Aged and Elderly Adults: Is Age of Onset Important?
Depp CA, Jin H, Mohamed S, Kaskow J, Moore DJ, Jeste DV. Bipolar Disorder in Middle-Aged and Elderly Adults: Is Age of Onset Important? The Journal Of Nervous And Mental Disease 2004, 192: 796-799. PMID: 15505527, DOI: 10.1097/01.nmd.0000145055.45944.d6.Peer-Reviewed Original ResearchConceptsLate-onset groupLate-life bipolar disorderAge of onsetBipolar disorderFamily historyLate-onset bipolar disorderAge 40 yearsContinuous variablesCognitive functioningRelationship of ageOlder patientsMedication useClinical featuresCross-sectional designMedication usageMean ageDepressive symptomsOverall psychopathologyDistinct syndromeElderly adultsMeasures of psychopathologyDisordersNeuropsychological functioningAgeNeurobiological aspects
1999
Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?
HAWKINS KA, MOHAMED S, WOODS SW. Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia? Psychological Medicine 1999, 29: 1-8. PMID: 10077288, DOI: 10.1017/s0033291798006990.Peer-Reviewed Original ResearchConceptsNovel antipsychoticsNegative symptomsNeuropsychological deficitsSevere psychiatric illnessNew antipsychotic medicationsTreatment of schizophreniaCognitive outcome dataAntipsychotic medicationConventional neurolepticsNeurodevelopmental aberrationsClinical effectivenessNew antipsychoticsUnderlying pathophysiologyClinical reasonsPsychiatric illnessImproved complianceOutcome dataFunctional capacityNeurological effectsAntipsychoticsAuditory hallucinationsNeurocognitive changesMedicationsNeural tissueSymptoms